About: The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route
Creator	Chrisley, Lisa Deming, Meagan Barnes, Robin Blackwelder, William Edelman, Robert Handwerger, Barry Heuser, Mark Pasetti, Marcela Siddiqui, Khan Sztein, Marcelo Toapanta, Franklin Wasserman, Steven
source	PMC
abstract	BACKGROUND: Reduced response to hepatitis B vaccines is associated with aging, confounding and comorbid conditions, as well as inadvertent subcutaneous (SC) inoculation. We hypothesized that the antibody and T cell-mediated immune responses (T-CMI) of elderly adults to a vaccine intended for intramuscular (IM) administration would be attenuated when deposited into SC fat, independent of confounding conditions. RESULTS: Fifty-two healthy, community dwelling elderly adults (65–82 years), seronegative for HBV, were enrolled in the SENIEUR protocol as a strictly healthy population. These seniors were randomized to receive a licensed alum-adjuvanted recombinant HBV vaccine either SC or IM, with the inoculum site verified by imaging. The response rates, defined as hepatitis B surface antibodies (HBsAb) ≥10 IU/L, were significantly lower in the elderly than in young adults, a group of 12, healthy, 21–34-year-old volunteers. Moreover, elderly participants who received the vaccine IM were significantly more likely to be responders than those immunized SC (54% versus 16%, p = 0.008). The low seroconversion rate in the IM group progressively declined with increasing age, and responders had significantly lower HBsAb titers and limited isotype responses. Moreover, T-CMI (proliferation and cytokine production) were significantly reduced in both percentage of responders and intensity of the response for both Th1 and Th2 subsets in the elderly. CONCLUSIONS: Our data demonstrate the blunted immunogenicity of SC inoculation as measured by peak titers and response rates. Further, the qualitative and quantitative deficits in B- and T-CMI responses to primary alum adjuvanted protein antigens persisted even in strictly healthy elderly populations with verified IM placement compared to younger populations. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT04162223. Registered 14 November 2019. Retrospectively registered.
has issue date	2020-04-28(xsd:dateTime)
bibo:doi	10.1186/s12979-020-00179-9
bibo:pmid	32355503
has license	cc-by
sha1sum (hex)	58524a1db06419f1109cbe4768eb3f2c424ebf89
schema:url	https://doi.org/10.1186/s12979-020-00179-9
resource representing a document's title	The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route
has PubMed Central identifier	PMC7187507
has PubMed identifier	32355503
schema:publication	Immun Ageing
resource representing a document's body	covid:58524a1db06419f1109cbe4768eb3f2c424ebf89#body_text
is schema:about of	named entity 'intramuscular' named entity 'vaccine' named entity 'confounding' named entity 'route' named entity 'vaccine' named entity 'vaccination' covid:arg/58524a1db06419f1109cbe4768eb3f2c424ebf89 named entity 'subcutaneous' named entity 'protocol' named entity 'comorbid conditions' named entity 'subcutaneous' named entity 'vaccine' named entity 'inoculation' named entity 'fat' named entity 'immune responses' named entity 'elderly persons' named entity 'conditions' named entity 'Pixels' named entity 'time lapse' named entity '8 women' named entity 'DEXA' named entity 'symptom' named entity 'confounders' named entity 'PBMC' named entity 'HBV' named entity 'estrogen' named entity 'vaccine' named entity 'correlation' named entity 'positive controls' named entity 'Deltoid muscle' named entity 'mAs' named entity 'inoculum' named entity 'comorbidities' named entity 'cytokine' named entity 'peripheral blood mononuclear cells' named entity 'immunization' named entity 'IL-2' named entity 'lymph nodes' named entity 'vaccination' named entity 'IL-4' named entity 'vaccine' named entity 'liqueur' named entity '5.2' named entity 'deltoid muscle' named entity 'vaccine' named entity 'cytokines' named entity 'Abbott Laboratories' named entity 'influenza vaccination' named entity 'IFN-γ' named entity 'covariate' named entity 'immune dysfunction' named entity 'image viewer' named entity 'CBA' named entity '7.2' named entity 'Merck' named entity 'immunization' named entity 'PBMC' named entity 'IL-2' named entity 'cholesterol' named entity 'Vitamin' named entity 'IL-2' named entity 'PBS' named entity 'IgG2' named entity 'HIV' named entity 'vaccine' named entity 'hepatitis' named entity '1, 2' named entity 'deltoid muscle' named entity 'antibody response' named entity 'intramuscular fat'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software